810
Participants
Start Date
October 27, 2023
Primary Completion Date
October 4, 2027
Study Completion Date
October 4, 2033
Hydroxyurea
Hydroxyurea, approximately 20-30 mg/kg/day, with modifications for toxicity or for mild marrow suppression
Hydroxyurea
Hydroxyurea 15-35 mg/kg/day based on PK-guided dosing, with modifications for toxicity for mild marrow suppression
Hospital Pediátrico David Bernardino, Luanda
Centre Hospitalier Monkole, Kinshasa
KEMRI/Wellcome Trust Research, Kilifi
Mbale Regional Hospital, Mbale
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Children's Hospital Medical Center, Cincinnati
OTHER